PBA
TGTX icon

Paradigm Biocapital Advisors’s TG Therapeutics TGTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,171,419
Closed -$37.1M – 36
2023
Q4 		$37.1M Sell
2,171,419
-1,447,596
-40% -$16.8M 1.74% 19
2023
Q3 		$30.3M Buy
+3,619,015
New +$50.5M 2.05% 19
2022
Q4 		– Sell
-1,505,479
Closed -$8.91M – 29
2022
Q3 		$8.91M Sell
1,505,479
-459,230
-23% -$3.01M 1.19% 25
2022
Q2 		$8.35M Buy
+1,964,709
New +$12.3M 1.66% 16

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Paradigm Biocapital Advisors's TGTX Position: Q1 2024 in Review

Paradigm Biocapital Advisors sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 2,171,419 shares — an estimated $37.1M sold.

Paradigm Biocapital Advisors first reported a position in TGTX in Q2 2022 and held it in 4 quarters. The position peaked at $37.1M in Q4 2023. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Paradigm Biocapital Advisors reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,171,419 TG Therapeutics shares in Q1 2024, an estimated $37.1M.
  • Paradigm Biocapital Advisors first reported a position in TG Therapeutics in Q2 2022 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's TG Therapeutics position peaked at $37.1M in Q4 2023.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2024, filed 15 May 2024.